Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy
This study is looking at whether adding Fecal Microbiota Transplantation (FMT) can help lymphoma patients who are receiving a standard treatment called Axicabtagene Ciloleucel (a type of CAR-T cell therapy). The main goal is to see if FMT can reduce gut-related side effects from antibiotics that patients often take. Researchers will also compare the safety and effectiveness of combining FMT with Axicabtagene Ciloleucel to just receiving Axicabtagene Ciloleucel alone. You may be able to join if you are at least 18 years old, have B-cell lymphoma, and are planning to receive Axicabtagene Ciloleucel. This study is currently recruiting about 40 participants, but its exact status is unclear.
- Study design
- This is an interventional study planning to enroll 40 participants. It compares the combination of FMT with CAR-T therapy to CAR-T therapy alone.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Safety and side effects will be measured throughout the study, which is expected to last an average of one year.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
At a glance
Conditions
NCT06218602
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
MD Anderson Cancer Center
Houston, Texasstudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Neeraj Saini, MD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Safety and adverse events (AEs)Through study completion; an average of 1 year.
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0